Search

Your search keyword '"Mercuri, Nicola Biagio"' showing total 439 results
Start Over Author "Mercuri, Nicola Biagio" Search Limiters Peer Reviewed
439 results on '"Mercuri, Nicola Biagio"'

7. Molecular and cellular determinants of L-Dopa-induced dyskinesia in Parkinson’s Disease

Author

Servillo, Federica, De Carluccio, Maria, Di Lazzaro, Giulia, Campanelli, Federica, Marino, Gioia, Natale, Giuseppina, Ledonne, Ada, Massaro Cenere, Mariangela, Paldino, Emanuela, Di Giuda, Daniela, Picca, Anna, Bove, Francesco, Di Iorio, Riccardo, Angeloni, Benedetta, Cimmino, Angelo Tiziano, Bellomo, Giovanni, Picconi, Barbara, Bentivoglio, Anna Rita, Mercuri, Nicola Biagio, Parnetti, Lucilla, Ghiglieri, Veronica, Viscomi, Maria Teresa, and Calabresi, Paolo

Published
2024
Full Text
View/download PDF

33. Positron Emission Tomography/Computed Tomography Imaging in Therapeutic Clinical Trials in Alzheimer's Disease: An Overview of the Current State of the Art of Research.

Author

Triumbari, Elizabeth Katherine Anna, Chiaravalloti, Agostino, Schillaci, Orazio, Mercuri, Nicola Biagio, and Liguori, Claudio

Subjects
POSITRON emission tomography, PATHOLOGY, COMPUTED tomography, ALZHEIMER'S disease, NEUROFIBRILLARY tangles, CEREBRAL amyloid angiopathy
Abstract

The integration of positron emission tomography/computed tomography (PET/CT) has revolutionized the landscape of Alzheimer's disease (AD) research and therapeutic interventions. By combining structural and functional imaging, PET/CT provides a comprehensive understanding of disease pathology and response to treatment assessment. PET/CT, particularly with 2-deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG), facilitates the visualization of glucose metabolism in the brain, enabling early diagnosis, staging, and monitoring of neurodegenerative disease progression. The advent of amyloid and tau PET imaging has further propelled the field forward, offering invaluable tools for tracking pathological hallmarks, assessing treatment response, and predicting clinical outcomes. While some therapeutic interventions targeting amyloid plaque load showed promising results with the reduction of cerebral amyloid accumulation over time, others failed to demonstrate a significant impact of anti-amyloid agents for reducing the amyloid plaques burden in AD brains. Tau PET imaging has conversely fueled the advent of disease-modifying therapeutic strategies in AD by supporting the assessment of neurofibrillary tangles of tau pathology deposition over time. Looking ahead, PET imaging holds immense promise for studying additional targets such as neuroinflammation, cholinergic deficit, and synaptic dysfunction. Advances in radiotracer development, dedicated brain PET/CT scanners, and Artificial Intelligence-powered software are poised to enhance the quality, sensitivity, and diagnostic power of molecular neuroimaging. Consequently, PET/CT remains at the forefront of AD research, offering unparalleled opportunities for unravelling the complexities of the disease and advancing therapeutic interventions, although it is not yet enough alone to allow patients' recruitment in therapeutic clinical trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer’s Disease

Author

La Barbera, Livia, Vedele, Francescangelo, Nobili, Annalisa, Krashia, Paraskevi, Spoleti, Elena, Latagliata, Emanuele Claudio, Cutuli, Debora, Cauzzi, Emma, Marino, Ramona, Viscomi, Maria Teresa, Petrosini, Laura, Puglisi- Allegra, Stefano, Melone, Marcello, Keller, Flavio, Mercuri, Nicola Biagio, Conti, Fiorenzo, and D’Amelio, Marcello

Published
2021
Full Text
View/download PDF

49. Poor Adherence to the Mediterranean Diet and Sleep Disturbances Are Associated with Migraine Chronification and Disability among an Adult Population in the Lazio Region, Italy.

Author

Bovenzi, Roberta, Noce, Annalisa, Conti, Matteo, Di Lauro, Manuela, Chiaramonte, Barbara, Morte, David Della, Stefani, Alessandro, De Lorenzo, Antonino, Mercuri, Nicola Biagio, and Albanese, Maria

Abstract

Lifestyle factors, such as diet and sleep quality, are receiving increasing interest as accessible therapeutic approaches to migraine. The Mediterranean diet (MD) has shown clear benefits in cardiovascular and metabolic diseases, as well as in sleep patterns. Here, our objective was to identify the impact of adherence to the MD and other lifestyle factors on the clinical burden of migraine. For this purpose, we enrolled 170 migraine patients and 100 controls, assessing the clinical disability of headache using standardized clinical scales (HIT-6 and MIDAS) in the migraineur cohort and lifestyle patterns in both groups through the PREDIMED score for MD adherence, the IPAQ scale for physical activity, and BMI. Subjects were also screened for sleep–wake disturbances based on the Pittsburgh Sleep Quality Index (PSQI). We found that migraine patients had lower adherence to the MD compared to the controls and that the HIT-6 scale had a significant negative relationship with MD adherence in patients with high-frequency episodic and chronic migraine. Additionally, in the same migraine patients, the presence of sleep–wake disturbances was correlated with greater migraine disability as assessed by the MIDAS score. In conclusion, this study found that among different lifestyle factors, poor adherence to the MD and the presence of sleep–wake disturbances were closely associated with migraine disability and chronification. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Early effect of onabotulinumtoxinA on EEG‐based functional connectivity in patients with chronic migraine: A pilot study.

Author

Conti, Matteo, Bovenzi, Roberta, Palmieri, Maria Giuseppina, Placidi, Fabio, Stefani, Alessandro, Mercuri, Nicola Biagio, and Albanese, Maria

Subjects
RESEARCH funding, RECEIVER operating characteristic curves, ELECTROENCEPHALOGRAPHY, HUMAN beings, PILOT projects, TREATMENT effectiveness, DESCRIPTIVE statistics, LONGITUDINAL method, BOTULINUM toxin, MIGRAINE
Abstract

Objective: In this pilot prospective cohort study, we aimed to evaluate, using high‐density electroencephalography (HD‐EEG), the longitudinal changes in functional connectivity (FC) in patients with chronic migraine (CM) treated with onabotulinumtoxinA (OBTA). Background: OBTA is a treatment for CM. Several studies have shown the modulatory action of OBTA on the central nervous system; however, research on migraine is limited. Methods: This study was conducted at the Neurology Unit of "Policlinico Tor Vergata," Rome, Italy, and included 12 adult patients with CM treated with OBTA and 15 healthy controls (HC). Patients underwent clinical scales at enrollment (T0) and 3 months (T1) from the start of treatment. HD‐EEG was recorded using a 64‐channel system in patients with CM at T0 and T1. A source reconstruction method was used to identify brain activity. FC in δ‐θ‐α‐β‐low‐γ bands was analyzed using the weighted phase‐lag index. FC changes between HCs and CM at T0 and T1 were assessed using cross‐validation methods to estimate the results' reliability. Results: Compared to HCs at T0, patients with CM showed hyperconnected networks in δ (p = 0.046, area under the receiver operating characteristic curve [AUC: 0.76‐0.98], Cohen's κ [0.65‐0.93]) and β (p = 0.031, AUC [0.68‐0.95], Cohen's κ [0.51‐0.84]), mainly involving orbitofrontal, occipital, temporal pole and orbitofrontal, superior temporal, occipital, cingulate areas, and hypoconnected networks in α band (p = 0.029, AUC [0.80‐0.99], Cohen's κ [0.42‐0.77]), predominantly involving cingulate, temporal pole, and precuneus. Patients with CM at T1, compared to T0, showed hypoconnected networks in δ band (p = 0.032, AUC [0.73‐0.99], Cohen's κ [0.53‐0.90]) and hyperconnected networks in α band (p = 0.048, AUC [0.58‐0.93], Cohen's κ [0.37‐0.78]), involving the sensorimotor, orbitofrontal, cingulate, and temporal cortex. Conclusion: These preliminary results showed that patients with CM presented disrupted EEG‐FC compared to controls restored by a single session of OBTA treatment, suggesting a primary central modulatory action of OBTA. Plain Language Summary: Chronic migraine, a disabling neurological condition, can be treated with onabotulinumtoxin A (OBTA) which works by blocking the release of pain‐related substances from a major nerve of the head. This study aimed to learn how OBTA affects the message pathways in the brain by comparing the electrical activity in the brains of patients with migraine who were treated with OBTA and the electrical activity in the brains of healthy people. We found that patients with migraine had significant changes in several brain areas that were restored after just one session of OBTA treatment, confirming a primary action of OBTA on the brain's electrical activity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results